Apoptosis and fibrosis in non-alcoholic fatty liver disease

Turkish Journal of Gastroenterology

Volumn 16, Issue 1, 2005, Pages 1-6

  Canbay, Ali ^a   Kip, Sertaç N ^b   Kahraman, Alişan ^a   Gieseler, Robert K ^c   Nayci, Ali ^d   Gerken, Guido ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c LTBH Medical Research Institute   (United States)

^d Mersin Medical School   (Turkey)

Author keywords

Apoptosis; Apoptotic bodies; Fibrosis; Inflammation; Non alcoholic steatohepatitis; Nonalcoholic fatty liver disease

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ALANINE AMINOTRANSFERASE; ALPHA CHEMOKINE; CASPASE 3; CASPASE 7; CASPASE 8; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; SOMATOMEDIN C; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; BILE DUCT LIGATION; CELL ACTIVATION; CELL STRAIN HEPG2; CHOLESTASIS; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FATTY ACID METABOLISM; GLUCOSE METABOLISM; HEPATITIS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INSULIN RESISTANCE; KUPFFER CELL; LIVER FIBROSIS; LIVER MITOCHONDRION; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; REVIEW; STEATOSIS; STELLATE CELL;

ANIMALS; APOPTOSIS; DISEASE PROGRESSION; FATTY LIVER; FIBROSIS; HUMANS;

EID: 17644428049     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137-45.
2. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
4. Angulo P, Alba LM, Petrovic LM, et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004; 41: 943-9.
5. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32: 689-92.
6. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9.
7. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002; 22: 185-94.
8. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
9. Canbay A, Higuchi H, Bronk SF, et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002; 123: 1323-30.
10. Jaeschke H. Inflammation in response to hepatocellular apoptosis. Hepatology 2002; 35: 964-6.
11. Canbay A, Guicciardi ME, Higuchi H, et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest 2003; 112: 152-9.
12. Takehara T, Tatsumi T, Suzuki T, et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 2004; 127: 1189-97.
13. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-43.
14. Savill J. Apoptosis in resolution of inflammation. Kidney Blood Press Res 2000; 23: 173-4.
15. Henson PM, Bratton DL, Fadok VA. The phosphatidylserine receptor: a crucial molecular switch? Nat Rev Mol Cell Biol 2001; 2: 627-33.
16. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12.
17. Faubion WA, Gores GJ. Death receptors in liver biology and pathobiology. Hepatology 1999; 29: 1-4.
18. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.
19. Thornberry NA. Caspases: key mediators of apoptosis. Chem Biol 1998; 5: R97-103.
20. Galle PR, Hofmann WJ, Walczak H, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182: 1223-30.
21. Galle PR, Krammer PH. CD95-induced apoptosis in human liver disease. Semin Liver Dis 1998; 18: 141-51.
22. Yoon JH, Gores GJ. Death receptor-mediated apoptosis and the liver. J Hepatol 2002; 37: 400-10.
23. Canbay A, Feldstein A, Baskin-Bey E, et al. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004; 308: 1191-6.
24. Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998; 282: 1714-7.
25. Maher JJ, Scott MK, Saito JM, et al. Adenovirus-mediated expression of cytokine-induced neutrophil chemoattractant in rat liver induces a neutrophilic hepatitis. Hepatology 1997; 25: 624-30.
26. Lawson JA, Fisher MA, Simmons CA, et al. Parenchymal cell apoptosis as a signal for sinusoidal sequestration and transendothelial migration of neutrophils in murine models of endotoxin and Fas-antibody-induced liver injury. Hepatology 1998; 28: 761-7.
27. Faouzi S, Burckhardt BE, Hanson JC, et al. Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway. J Biol Chem 2001; 276: 49077-82.
28. Lauber K, Bohn E, Krober SM, et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003; 113: 717-30.
29. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-9.
30. Patel T, Roberts LR, Jones BA, et al. Dysregulation of apoptosis as a mechanism of liver disease: an overview. Semin Liver Dis 1998; 18: 105-14.
31. Kiener PA, Davis PM, Starling GC, et al. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med 1997; 185: 1511-6.
32. Geske FJ, Monks J, Lehman L, Fadok VA. The role of the macrophage in apoptosis: hunter, gatherer, and regulator. Int J Hematol 2002; 76: 16-26.
33. Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003; 38: 1188-98.
34. Jaeschke H, Fisher MA, Lawson JA, et al. Activation of caspase 3 (CPP32)-like proteases is essential for TNF-alpha-induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. J Immunol 1998; 160: 3480-6.
35. Ziol M, Tepper M, Lohez M, et al. Clinical and biological relevance of hepatocyte apoptosis in alcoholic hepatitis. J Hepatol 2001; 34: 254-60.
36. Jaeschke H. Neutrophil-mediated tissue injury in alcoholic hepatitis. Alcohol 2002; 27: 23-7.
37. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50.
38. Maher JJ. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis 2001; 21: 417-26.
39. Paik YH, Schwabe RF, Bataller R, et al. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003; 37: 1043-55.
40. Gressner AM. Mediators of hepatic fibrogenesis. Hepatogastroenterology 1996; 43: 92-103.
41. Ribeiro PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99: 1708-17.
42. Feldstein A, Canbay A, Guicciardi ME, et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003; 39: 978-83.
43. Bantel H, Lugering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004; 40: 1078-87.
44. Tinel M, Berson A, Vadrot N, et al. Subliminal Fas stimulation increases the hepatotoxicity of acetaminophen and bromobenzene in mice. Hepatology 2004; 39: 655-66.
45. Canbay A, Chen S-Y, Gieseler RK, et al. Overweight patients are more susceptible for acute liver failure. Hepatogastroenterology 2005; in press.
46. Valentino KL, Gutierrez M, Sanchez R, et al. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int J Clin Pharmacol Ther 2003; 41: 441-9.
47. Eichhorst ST, Krueger A, Muerkoster S, et al. Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice. Nat Med 2004; 10: 602-9.
48. Guicciardi ME, Gores GJ. Cheating death in the liver. Nat Med 2004; 10: 587-8.